CYP3A4 Inhibitors

Strong: ≥5-fold increase in the plasma AUC values (>80% decrease in clearance)

Moderate: ≥2-fold increase in the plasma AUC values (50–80% decrease in clearance)

Weak: ≥1.25-fold and <2-fold increase in the plasma AUC values (20–50% decrease in clearance)

Strong inhibitors

protease inhibitors
- boceprevir
- ritonavir
- indinavir
- nelfinavir
- saquinavir
macrolide antibiotics
- clarithromycin
- erythromycin
- telithromycin
ceritinib
mibefradil
nefazodone
ribociclib
tucatinib
chloramphenicol
azole antifungals
- ketoconazole
- itraconazole
- posaconazole
- voriconazole
cobicistat
green tea extract
grape seed extract
dillapiole
apigenin

Moderate inhibitors

amiodarone
aprepitant
ciprofloxacin
conivaptan
crizotinib
rutin
tofisopam
calcium channel blockers
- verapamil
- diltiazem
azole antifungals
- fluconazole
- miconazole
bergamottin
cyclosporine
donedarone
fluvoxamine
imatinib
valerian

Weak inhibitors

berberine
buprenorphine
cafestol (in unfiltered coffee)
cilostazol
cimetidine
fosaprepitant
lomitapide
orphenadrine
omeprazole
quercetin
ranitidine
ranolazine
tacrolimus
ticagrelor
valproic acid
amlodipine
azithromycin

Inhibitors of unspecified potency

cannabidiol
dithiocarbamate
mifepristone
norfloxacin
antiretroviral drugs
- delavirdine
gestodene
star fruit
milk thistle
niacin
ginkgo biloba
sesamin
piperine
isoniazid
serenoa